BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 7580171)

  • 1. Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.
    Lurie S; O'Quinn A
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):41-50. PubMed ID: 7580171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The medical treatment of attention deficit hyperactivity disorder (ADHD) with amphetamines in children and adolescents].
    Frölich J; Banaschewski T; Spanagel R; Döpfner M; Lehmkuhl G
    Z Kinder Jugendpsychiatr Psychother; 2012 Sep; 40(5):287-99; quiz 299-300. PubMed ID: 22869222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing stimulant medication for attention-deficit/hyperactivity disorder.
    Wender EH
    Pediatr Rev; 2001 Jun; 22(6):183-90. PubMed ID: 11389305
    [No Abstract]   [Full Text] [Related]  

  • 4. Attention deficit hyperactivity disorder in children.
    Ramchandani P; Joughin C; Zwi M
    Clin Evid; 2002 Dec; (8):280-90. PubMed ID: 12603883
    [No Abstract]   [Full Text] [Related]  

  • 5. Attention deficit hyperactivity disorder in children.
    Ramchandani P; Joughin C; Zwi M
    Clin Evid; 2002 Jun; (7):262-71. PubMed ID: 12230649
    [No Abstract]   [Full Text] [Related]  

  • 6. An update on attention deficit disorder.
    Harv Ment Health Lett; 2004 May; 20(11):4-7. PubMed ID: 15153391
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient.
    Kollins SH
    J Clin Psychiatry; 2003; 64 Suppl 11():14-8. PubMed ID: 14529325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.
    Williams RJ; Goodale LA; Shay-Fiddler MA; Gloster SP; Chang SY
    Am J Addict; 2004; 13(4):381-9. PubMed ID: 15370936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of attention-deficit/hyperactivity disorder.
    Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R
    Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulant therapy in attention deficit/hyperactivity disorder.
    Baldwin RL
    J Ark Med Soc; 2003 Dec; 100(6):203-6. PubMed ID: 14661403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of attention-deficit-hyperactivity disorder.
    Elia J; Ambrosini PJ; Rapoport JL
    N Engl J Med; 1999 Mar; 340(10):780-8. PubMed ID: 10072414
    [No Abstract]   [Full Text] [Related]  

  • 12. Illicit use of prescription ADHD medications on a college campus: a multimethodological approach.
    DeSantis AD; Webb EM; Noar SM
    J Am Coll Health; 2008; 57(3):315-24. PubMed ID: 18980888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate-related growth impairment.
    Holtkamp K; Peters-Wallraf B; Wüller S; Pfäaffle R; Herpertz-Dahlmann B
    J Child Adolesc Psychopharmacol; 2002; 12(1):55-61. PubMed ID: 12014596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate versus dextroamphetamine in ADHD.
    Efron D
    J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):500. PubMed ID: 10230180
    [No Abstract]   [Full Text] [Related]  

  • 17. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.
    Kociancic T; Reed MD; Findling RL
    Expert Opin Drug Saf; 2004 Mar; 3(2):93-100. PubMed ID: 15006715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007.
    Janols LO; Liliemark J; Klintberg K; von Knorring AL
    Nord J Psychiatry; 2009 Nov; 63(6):508-16. PubMed ID: 19958258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.